CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strikes Licensing Deal with Cannadips CBD

British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently entered a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD. An article discussing the company reads, “The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://cnw.fm/V6p4Q). . . . ‘This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination. We are excited to be developing a category of products with best-in-class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine,’ Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners Corporation (Cannadips), stated in a news release.”

To view the full article, visit http://cnw.fm/QNhR3

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM)-Enabled CBD Infused Powders Available for Sale Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that its DehydraTECH(TM)-enabled CBD infused powders are now available for sale across the U.S. to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability. Consumers of both CBD/hemp and cannabis have recently become concerned about the potency and safety of the oil extract products they are purchasing. Lexaria’s patented DehydraTECH(TM) technology and powder processing methodology, similar to a pasteurization technique in some ways, helps to not only preserve cannabinoid potency but also to reduce or eliminate microbiological growth and cannabinoid degradation.

To view the full press release, visit http://cnw.fm/cvZ6x

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology

British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another. . . . The continued preference for the rapid delivery of inhaled drug substances has led many researchers to seek alternatives beyond deterrence campaigns. DehydraTECH’s newest formulation was recently shown to deliver 811% more CBD into the bloodstream than generic industry control formulations, nearly doubling the capacity of existing DehydraTECH technology. It was additionally shown to deliver 1,937% more CBD across the blood-brain barrier into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology (http://cnw.fm/89Soz).”

To view the full article, visit http://cnw.fm/95Fyc

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW – LA Black Entrepreneurs Frustrated by Unresponsive Marijuana Equity Program

The establishment of a program meant to provide marijuana permits to people who have been affected by the war against drugs in Los Angeles has been marred by delays, scandal, and bureaucratic blunders. This has resulted in the loss of thousands of dollars for some of the intended beneficiaries.

Speaking to the Guardian, black entrepreneurs and marijuana activists said that the beleaguered social equity program had left potential business owners on a list whose approval timeline is uncertain, and this has resulted in irreparable damages to the finances of the businesses in question. It has also prevented them from opening cannabis retail outlets they have been planning on for several years.

Estimates from advocates of the social equity program indicate that out of the one hundred businesses on track to receive licenses, less than twenty of them are from black communities. The advocates further said that black communities are among the disproportionately affected communities that were targeted by marijuana arrests and discrimination. They also noted that applicants for the social equity programs are facing precarious futures even now.

In the meantime, white business owners are currently leading the booming Los Angeles marijuana sector.

Lanaisha Edwards asked how the other people who were not affected by prohibition are awarded licenses and make millions of dollars out of their suffering. Edwards is a South LA native who had applied for a marijuana retail license through the social equity program. She noted that prohibition led to the destruction of many families, and it would be beneficial if they managed to end prohibition and create wealth in the process. However, there is a possibility that the businesses are not going to reap any benefits from the program.

The social equity program was launched in 2018, to right the wrong of criminalization by awarding licenses to people impacted by the war against drugs, while eliminating barriers hindering people from opening small businesses. Residents from disproportionately affected communities would be eligible for marijuana licenses also if they were low-income and had previously been convicted for marijuana crimes.

Rabin Woods, a 57-year-old male previously arrested for marijuana offenses in 1983, said that the program was supposed to be their compensation, but currently, he is struggling to open a marijuana retail outlet in LA.

Blacks and Latinos have been victims of profiling by law enforcement in the U.S. with data consistently showing that blacks were four times more likely to be arrested for marijuana crimes than whites.

According to the owner and co-founder of the California Minority Alliance, Virgil Grant, only six out of the 200 permits previously issued in LA were owned by black people, and even fewer were Latino-owned.

There was hope among LA residents that the social equity program would bridge the racial gap after recreational marijuana legalization, but it is evident that it is not happening any time soon.

The applicants for marijuana licenses complained that most of the candidates who made it to the top 100 were not representatives of people impacted by prohibition. They also said that eligibility was not based on race or geographical boundaries, which allowed a large number of applicants who were not directly affected war against drugs to benefit at the expense of the intended beneficiaries.

Analysts believe that the entire cannabis industry, including Lexara Biosciences Corp. (CSE: LXX) (OTCQX: LXRP), would like to see the complaints of the social equity program investigated and resolved if mistakes were made during the implementation of the program.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://cnw.fm/4wHA6). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target the central nervous system. . . . Lexaria’s research and development showed that DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology, according to the company’s news release.”

To view the full article, visit http://cnw.fm/h7lGM

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

420 with CNW – Mexican Lawmakers Get Set to Legalize Pot in April

As the legislature resumes their sessions next month in Mexico, lawmakers are preparing to push for marijuana reform since they have been seen circulating an amended bill amongst themselves. The amended legislation seeks to legalize and regulate cannabis sales within Mexico.

The amended legislation was filed by the Justice and Health committees. It would allow possession of a maximum of 28 grams of marijuana per adult and cultivation of a maximum of six plants for personal use. It also has a provision allowing people to apply for a license to carry more than 28 grams of weed but not above 200 grams.

Next week Senator Ricardo Monreal Avial will be holding a meeting with the Interior Secretary Olga Sanchez Cordero and the legal advisor to the president, Julio Scherer, to discuss the marijuana reform bill since the proposed measure is not final, and he considers it as a next step process.

The amended legislation has a provision where people found carrying marijuana ranging from 28 grams to 200 grams would be charged a fine of about $560. Stringent measures would be taken against adults found possessing more than 200 grams of weed.

A new regulatory body, the Mexican Cannabis Institute, would be created to issue business licenses and create rules for the marijuana market. The legislation also aims to promote social equity by prioritizing people from areas impacted by prohibition when issuing cultivation permits.

According to Milenio, the Mexican Marijuana Institute would also be allowed to fund research on the cultivation of marijuana, which is to be sold commercially through grants.

The amended bill comes a year plus after the Supreme Court in Mexico passed a ruling to end federal laws prohibiting cultivation and possession of marijuana deeming it unconstitutional. Since then, lawmakers have been working to establish a scheme allowing recreational marijuana in the country.

The Senate made progress with the bill by holding several public gatherings to educate the public, and in one of the meetings, they featured a former White House drug czar, but the legislature did not meet the court-appointed deadline for the approval of the legislation, which was October 2019; therefore, they requested for an extension. The Supreme Court extended the deadline to April 30, 2020.

The new bill has some minor changes, such as amending the business licensing scheme where it classifies it into five types of licenses. These include cultivation, transformation/processing, marketing, exports, and imports as well as research.

Montreal said that some leaders are not in favor of the measure, but the lawmakers are hoping to legalize marijuana before the deadline.

It would be interesting to hear what cannabis companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) have to say about the implications of legalizing recreational marijuana in Mexico.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW – Arkansas Piles Pressure on Licensed Medical Marijuana Dispensaries to Open

On the morning of January 19, local media outlets published several stories updating the residents of Arkansas on medical marijuana, as the opening of dispensaries continues at a slow pace. Half of the state’s licensed dispensaries are not yet operational and the state is moving to compel them to open or risk losing their licenses.

The Medical Marijuana Commission in Arkansas is planning to meet with all the dispensary owners and marijuana growing companies to discuss and determine whether their licenses should be extended for another year. There are 32 dispensary operators and five cannabis growing companies.

It is one year since the first licenses were issued, and 16 dispensaries are yet to open. The companies that have not opened or made any progress may lose their licenses, the commissioners hinted.

Although voters legalized medical marijuana through the ballot back in 2016, the state has made very little progress. The licenses for medical marijuana dispensaries were issued in 2019, and the first dispensary was opened in May the same year. So far, 16 dispensaries are operational, and they have so far sold 5,000 pounds of marijuana for not less than $33 million. Arkansas residents with medical marijuana cards are about 35,000.

Many operational dispensaries are looking to start growing their own marijuana. The spokesman for the Arkansas Department of Finance and Administration, Scott Hardin, said that the dispensaries are also licensed to cultivate marijuana, but they had opted to start with the shop outlet so that they could become operational faster.

According to some business representatives, many businesses are planning to grow the amount of marijuana permitted by the state, which is 50 mature plants. The dispensaries include Acanza in Fayetteville, The ReLeaf Center in Bentonville, and The Source in Bentonville. Currently, the three businesses are buying cannabis from the three cultivation sites in the state. According to Arkansas law, dispensaries within the state may only purchase marijuana for their shops from the cultivation sites within Arkansas.

Hardin said that when the four dispensaries located in Northwest applied for their licenses, they were approved to add a cultivation location. But because the state must first inspect the cultivation location, the four dispensaries could not begin their cultivation process.

The state of Arkansas is working to establish rules and regulations for dispensaries with cultivation locations so that they can also be allowed to process their marijuana once its harvested.

Analysts believe that the entire cannabis industry, including Lexaria Biosciences Corp. (CSE: LXX) (OTCQX: LXRP), would be glad to see all licensed dispensaries open for business so that the people of Arkansas can have many options to choose from.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in its current California market and across the United States. According to the update, Lexaria’s DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage effect derived from multi-spectrum oils in an attempt to get around this problem. “Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Lexaria Bioscience CEO Chris Bunka stated in the news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets that are either recreational or medical cannabis states, while preserving the brand rights as states come online through regulation.”

To view the full press release, visit http://cnw.fm/4qN9T

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Why the Thai Military Regards Medical Marijuana as Top Priority

The Ministry of Public Health in Thailand launched the first full-time medical marijuana clinic in Bangkok earlier this month. The launch was led by the conservative, military-dominated government, whose main aim is to make Thailand the regional producer and distributor of medical marijuana.

Marijuana extracts are approved for treating a wide range of diseases and conditions such as Alzheimer’s, anxiety, cancer, epilepsy and Parkinson’s disease.

More clinics will be opened in greater Bangkok as promised by the government, and through a specialized smartphone app, patients would be able to book appointments.

Dr. Ganja, a mascot, is campaigning for the government to promote medical marijuana. Dr. Ganja is an approachable and level –headed scientist. Another supporter of legal marijuana is the Thailand Prime Minister who is also a former military general, Prayut Chan-o-cha.

Discussed below is where the push for developing the legal marijuana industry in Thailand started and whether it could be the gateway for further drug use liberalization in South East Asia.

When the Push Towards Medical Marijuana Started in Thailand

Marijuana was outlawed in Thailand in 1935, and before that ban, it had always been a part of traditional medicine and a cooking ingredient. It had also been used as a form of pain relief.

The legalization of medical marijuana in Thailand took place in December 2018, making Thailand the first country in South East Asia to legalize marijuana. It was legalized through an amendment of the 1979 Narcotic Act, thereby approving the use of marijuana for medicinal and research purposes.

The Ministry of Health in Thailand has a website containing information about marijuana cultivation, medical research, and the status of marijuana in Thailand, and the public can browse through the website to educate themselves.

The cultivation of medical marijuana can now be done by government agencies, institutions of higher education, agricultural producers, entrepreneurs, and medical professionals.

The first medical marijuana research institution was launched in 2019 by Rangit University in Bangkok. Harsh penalties are still being imposed on those found possessing and trafficking marijuana.

Why Thailand Decided to Promote Medical Marijuana

The military-dominated government recognized the vast business opportunity and tax revenue to ensue from the legalization of medical marijuana, and this could have been a strong motivator for legalizing the industry.

Besides, having watched how the marijuana market in North America has grown, increased revenues, and created thousands of jobs, the Thai government had to venture into the medical marijuana industry.

Prohibition Partners is a marijuana market research firm, and it estimated that by 2024, the Asian medical marijuana market could be worth $8.4 billion. The managing director of Prohibition Partners, Daragh Anglim, said that a well regulated medical marijuana market across Asia could help transform patients’ health, farmers, and the economy. The firm further estimated that Thailand’s legal marijuana market could be worth about $958 million by 2024.

Being one of the largest medical tourism destinations across the globe, Thailand officials would like to provide medical tour packages such as detox, massages and other wellness services using medical marijuana products, said the tourism minister, Pipat Ratchakitprakan.

Could it Be the Gateway to the Broader Legalization of Marijuana?

A recent poll shows that 80% of Thai citizens are in favor of full legalization of marijuana, reported the Bangkok Post. This indicates that Thailand could be on the path of legalizing adult-use marijuana, but the military is still opposed to adult-use recreational marijuana.

Nevertheless, the steps that they have taken to avail medical marijuana to the patients who need it the most may have won applause from industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Neutra Corp. (OTC: NTRR) who would like patients from all parts of the world to have the option of using medical marijuana to manage their conditions.

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Agreement to Provide DehydraTECH(TM) Technology to Cannadips CBD

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced that it has reached a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD, the Original Smokeless CBD Dip Brand. According to the update, each tin of Cannadips contains 15 pouches, each with 10mg of hemp-derived CBD, and includes only natural sweeteners with no tobacco or nicotine. Already established as the leader in CBD oral delivery, Lexaria has been working behind the scenes with the Boldt Runners team to elevate the product experience. “In our quest to create the ultimate smokeless, oral cannabinoid experience for our customers, we found that the DehydraTECH technology solves many challenges and propels the product forward as we pioneer this product category,” The Boldt Runners Corporation Founder and Chief Executive Officer Case Mandel said in the news release. “Through our strong distribution partnership with Kretek International, and our family of strategic retail partners including Sheetz, Kwiktrip, and Circle K we are stoked for the DehydraTECH technology to shine through our tins.”

To view the full press release, visit http://cnw.fm/JFU8k

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.